Isolation of recombinant hirudin by preparative high-performance liquid chromatography.
The purification of recombinant hirudin variant 2-Lys47 (rHV2-Lys47), produced by a genetically engineered yeast strain, is described. rHV2-Lys47 expressed and secreted into the culture medium was the starting material for the purification process of hirudin from the culture broth after cell harvesting by centrifugation. Initial purification of the product by preparative reversed-phase high-performance liquid chromatography (HPLC) using step-gradient elution, followed by precipitation of rHV2-Lys47 in the presence of acetone, removed most of the contaminants from the culture medium. The pure product was obtained by successive preparative anion-exchange and reversed-phase HPLC on silica based stationary phases. Characterization of the final product by analytical HPLC, isoelectric focusing gel electrophoresis, quantitative amino acid composition and sequence analysis did not reveal any contaminants. Liquid secondary ion mass spectrometry was used to confirm its primary structure. The isolated product was tested in an inhibition assay of human alpha-thrombin and proved to be fully active.
Bischoff
R
R
Transgene S.A., Analytical and Process Development Division, Strasbourg, France.
Clesse
D
D
Whitechurch
O
O
Lepage
P
P
Roitsch
C
C
D002851:Chromatography, High Pressure Liquid; D002852:Chromatography, Ion Exchange; D004926:Escherichia coli / Q000378:metabolism; D006629:Hirudins / Q000302:isolation & purification* / Q000494:pharmacology; D007525:Isoelectric Focusing; D013058:Mass Spectrometry; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000494:pharmacology; D012441:Saccharomyces cerevisiae / Q000378:metabolism; D013056:Spectrophotometry, Ultraviolet; D013917:Thrombin / Q000037:antagonists & inhibitors
D006629:Hirudins; D011994:Recombinant Proteins; D013917:Thrombin